6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
.	.	.	.	.	N	O

Myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)]	NN	)]	)]	)]	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
Infusion	NNP	infusion	infusion	infus	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)]	NN	)]	)]	)]	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
Lysis	NNP	lysis	lysis	lysi	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)]	NN	)]	)]	)]	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O

Other	JJ	other	other	other	N	O
Malignancies	NNPS	malignancies	malignancy	malign	N	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)]	NN	)]	)]	)]	N	O

Extravasation	NNP	extravasation	extravasation	extravas	Y	B-AdverseReaction
injury	NN	injury	injury	injuri	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)]	NN	)]	)]	)]	N	O

Most	JJS	most	most	most	N	O

common	JJ	common	common	common	N	O
non	SYM	non	non	non	N	O
-	:	-	-	-	N	O
hematologic	JJ	hematologic	hematologic	hematolog	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
for	IN	for	for	for	N	O
CLL	NNP	cll	cll	cll	Y	O
(	(	(	(	(	N	O
frequency	NN	frequency	frequency	frequenc	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
pyrexia	JJ	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
non	NN	non	non	non	N	O
-	:	-	-	-	N	O
hematologic	JJ	hematologic	hematologic	hematolog	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
for	IN	for	for	for	N	O
NHL	NNP	nhl	nhl	nhl	N	O
(	(	(	(	(	N	O
frequency	NN	frequency	frequency	frequenc	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
nausea	JJ	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
anorexia	NN	anorexia	anorexia	anorexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
hematologic	NN	hematologic	hematologic	hematolog	N	B-AdverseReaction
abnormalities	NNS	abnormalities	abnormality	abnorm	N	I-AdverseReaction
for	IN	for	for	for	N	O
both	DT	both	both	both	N	O
indications	NNS	indications	indication	indic	N	O
(	(	(	(	(	N	O
frequency	NN	frequency	frequency	frequenc	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
lymphopenia	JJ	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Teva	NNP	teva	teva	teva	N	O
Pharmaceuticals	NNP	pharmaceuticals	pharmaceutical	pharmaceut	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
896	CD	896	896	896	N	O
-	:	-	-	-	N	O
5855	CD	5855	5855	5855	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O

Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Chronic	NNP	chronic	chronic	chronic	N	O
Lymphocytic	NNP	lymphocytic	lymphocytic	lymphocyt	N	O
Leukemia	NNP	leukemia	leukemia	leukemia	Y	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
in	IN	in	in	in	N	O
153	CD	153	153	153	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
CLL	NNP	cll	cll	cll	Y	O
studied	VBD	studied	studied	studi	N	O
in	IN	in	in	in	N	O
an	DT	an	an	an	N	O
active	JJ	active	active	activ	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
,	,	,	,	,	N	O
randomized	VBN	randomized	randomized	random	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
45	CD	45	45	45	N	O
-	:	-	-	-	N	O
77	CD	77	77	77	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
63%	CD	63%	63%	63%	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
100%	CD	100%	100%	100%	N	O
white	JJ	white	white	white	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
treatment	NN	treatment	treatment	treatment	N	O
naive	JJ	naive	naive	naiv	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
started	VBD	started	started	start	N	O
the	DT	the	the	the	N	O
study	NN	study	study	studi	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
100	CD	100	100	100	N	O
mg	NNS	mg	mg	mg	N	O
m	RB	m	m	m	N	O
2	CD	2	2	2	N	O
intravenously	RB	intravenously	intravenously	intraven	N	O
over	IN	over	over	over	N	O
30	CD	30	30	30	N	O
minutes	NNS	minutes	minute	minut	N	O
on	IN	on	on	on	N	O
Days	NNS	days	day	day	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
every	DT	every	every	everi	N	O
28	CD	28	28	28	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
according	VBG	according	according	accord	N	O
to	TO	to	to	to	N	O
NCI	NNP	nci	nci	nci	N	O
CTC	NNP	ctc	ctc	ctc	N	O
v	NN	v	v	v	N	O
.	.	.	.	.	N	O
2.0	CD	2.0	2.0	2.0	N	O
.	.	.	.	.	N	O

Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
hematologic	JJ	hematologic	hematologic	hematolog	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
group	NN	group	group	group	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
frequency	NN	frequency	frequency	frequenc	N	O
greater	JJR	greater	greater	greater	N	O
than	IN	than	than	than	N	O
15%	CD	15%	15%	15%	N	O
were	VBD	were	were	were	N	O
pyrexia	NNS	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
24%	CD	24%	24%	24%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
seen	VBN	seen	seen	seen	N	O
frequently	RB	frequently	frequently	frequent	N	O
in	IN	in	in	in	N	O
one	CD	one	one	one	N	O
or	CC	or	or	or	N	O
more	JJR	more	more	more	N	O
studies	NNS	studies	study	studi	N	O
included	VBD	included	included	includ	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
malaise	NN	malaise	malaise	malais	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
weakness	NN	weakness	weakness	weak	Y	B-AdverseReaction
;	:	;	;	;	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
;	:	;	;	;	N	O
somnolence	NN	somnolence	somnolence	somnol	Y	B-AdverseReaction
;	:	;	;	;	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
;	:	;	;	;	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
;	:	;	;	;	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
;	:	;	;	;	N	O
mucosal	CC	mucosal	mucosal	mucos	N	B-AdverseReaction
inflammation	NN	inflammation	inflammation	inflamm	Y	I-AdverseReaction
and	CC	and	and	and	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
.	.	.	.	.	N	O

Worsening	VBG	worsening	worsening	worsen	N	B-AdverseReaction
hypertension	NN	hypertension	hypertension	hypertens	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
4	CD	4	4	4	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CLL	NNP	cll	cll	cll	Y	O
trial	NN	trial	trial	trial	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
none	NN	none	none	none	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
chlorambucil	NN	chlorambucil	chlorambucil	chlorambucil	N	O
.	.	.	.	.	N	O

Three	CD	three	three	three	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
4	CD	4	4	4	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
described	VBN	described	described	describ	N	O
as	IN	as	a	as	N	O
a	DT	a	a	a	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
crisis	NN	crisis	crisis	crisi	N	I-AdverseReaction
and	CC	and	and	and	N	O
were	VBD	were	were	were	N	O
managed	VBN	managed	managed	manag	N	O
with	IN	with	with	with	N	O
oral	JJ	oral	oral	oral	N	O
medications	NNS	medications	medication	medic	N	O
and	CC	and	and	and	N	O
resolved	VBN	resolved	resolved	resolv	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
frequent	JJ	frequent	frequent	frequent	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
study	VB	study	study	studi	N	O
withdrawal	NN	withdrawal	withdrawal	withdraw	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
were	VBD	were	were	were	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
contains	VBZ	contains	contains	contain	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
emergent	JJ	emergent	emergent	emerg	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
attribution	NN	attribution	attribution	attribut	N	O
,	,	,	,	,	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
either	DT	either	either	either	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	JJ	randomized	randomized	random	N	O
CLL	NNP	cll	cll	cll	Y	O
clinical	JJ	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
Hematologic	NNP	hematologic	hematologic	hematolog	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
Randomized	NNP	randomized	randomized	random	N	O
CLL	NNP	cll	cll	cll	Y	O
Clinical	NNP	clinical	clinical	clinic	N	O
Study	NNP	study	study	studi	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O

Number	NNP	number	number	number	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O

TREANDA	NNP	treanda	treanda	treanda	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
153	CD	153	153	153	N	O
)	)	)	)	)	N	O
Chlorambucil	NNP	chlorambucil	chlorambucil	chlorambucil	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
143	CD	143	143	143	N	O
)	)	)	)	)	N	O

System	NNP	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
term	NN	term	term	term	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O

Total	JJ	total	total	total	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
121	CD	121	121	121	N	O
(	(	(	(	(	N	O
79	CD	79	79	79	N	O
)	)	)	)	)	N	O
52	CD	52	52	52	N	O
(	(	(	(	(	N	O
34	CD	34	34	34	N	O
)	)	)	)	)	N	O
96	CD	96	96	96	N	O
(	(	(	(	(	N	O
67	CD	67	67	67	N	O
)	)	)	)	)	N	O
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
17	CD	17	17	17	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
31	CD	31	31	31	N	O
(	(	(	(	(	N	O
20	CD	20	20	20	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
21	CD	21	21	21	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Pyrexia	$	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
36	CD	36	36	36	N	O
(	(	(	(	(	N	O
24	CD	24	24	24	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Immune	NNP	immune	immune	immun	N	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Infection	NN	infection	infection	infect	Y	B-AdverseReaction
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Herpes	NNP	herpes	herpes	herp	N	B-AdverseReaction
simplex	VBD	simplex	simplex	simplex	N	I-AdverseReaction
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hyperuricemia	$	hyperuricemia	hyperuricemia	hyperuricemia	Y	B-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	IN	cough	cough	cough	Y	B-AdverseReaction
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

The	DT	the	the	the	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
4	CD	4	4	4	N	O
hematology	NN	hematology	hematology	hematolog	N	O
laboratory	JJ	laboratory	laboratory	laboratori	N	O
test	NN	test	test	test	N	O
values	NNS	values	value	valu	N	O
by	IN	by	by	by	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	JJ	randomized	randomized	random	N	O
CLL	NNP	cll	cll	cll	Y	O
clinical	NN	clinical	clinical	clinic	N	O
study	NN	study	study	studi	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
findings	NNS	findings	finding	find	N	O
confirm	VBP	confirm	confirm	confirm	N	O
the	DT	the	the	the	N	O
myelosuppressive	JJ	myelosuppressive	myelosuppressive	myelosuppress	N	B-AdverseReaction
effects	NNS	effects	effect	effect	N	I-AdverseReaction
seen	VBN	seen	seen	seen	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
.	.	.	.	.	N	O

Red	JJ	red	red	red	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
transfusions	NNS	transfusions	transfusion	transfus	N	O
were	VBD	were	were	were	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
20%	CD	20%	20%	20%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
compared	VBN	compared	compared	compar	N	O
with	IN	with	with	with	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
chlorambucil	NN	chlorambucil	chlorambucil	chlorambucil	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Hematology	NNP	hematology	hematology	hematolog	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
in	IN	in	in	in	N	O
Patients	NNPS	patients	patient	patient	N	O
Who	WP	who	who	who	N	O
Received	VBD	received	received	receiv	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
or	CC	or	or	or	N	O
Chlorambucil	NNP	chlorambucil	chlorambucil	chlorambucil	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
Randomized	NNP	randomized	randomized	random	N	O
CLL	NNP	cll	cll	cll	Y	O
Clinical	NNP	clinical	clinical	clinic	N	O
Study	NNP	study	study	studi	N	O

TREANDA	NNP	treanda	treanda	treanda	N	O
N	NNP	n	n	n	N	O
150	CD	150	150	150	N	O
ChlorambucilN	NNP	chlorambuciln	chlorambuciln	chlorambuciln	N	O
141	CD	141	141	141	N	O

Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormality	NNP	abnormality	abnormality	abnorm	N	O
All	NNP	all	all	all	N	O
Gradesn	NNP	gradesn	gradesn	gradesn	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
n	NNS	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
All	DT	all	all	all	N	O
Gradesn	NNP	gradesn	gradesn	gradesn	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O
n	NNS	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
134	CD	134	134	134	N	O
(	(	(	(	(	N	O
89	CD	89	89	89	N	O
)	)	)	)	)	N	O
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
115	CD	115	115	115	N	O
(	(	(	(	(	N	O
82	CD	82	82	82	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O

Platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
116	CD	116	116	116	N	O
(	(	(	(	(	N	O
77	CD	77	77	77	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O
110	CD	110	110	110	N	O
(	(	(	(	(	N	O
78	CD	78	78	78	N	O
)	)	)	)	)	N	O
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O

Leukocytes	NNS	leukocytes	leukocyte	leukocyt	N	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
92	CD	92	92	92	N	O
(	(	(	(	(	N	O
61	CD	61	61	61	N	O
)	)	)	)	)	N	O
42	CD	42	42	42	N	O
(	(	(	(	(	N	O
28	CD	28	28	28	N	O
)	)	)	)	)	N	O
26	CD	26	26	26	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Lymphocytes	NNS	lymphocytes	lymphocyte	lymphocyt	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
102	CD	102	102	102	N	O
(	(	(	(	(	N	O
68	CD	68	68	68	N	O
)	)	)	)	)	N	O
70	CD	70	70	70	N	O
(	(	(	(	(	N	O
47	CD	47	47	47	N	O
)	)	)	)	)	N	O
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
19	CD	19	19	19	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
113	CD	113	113	113	N	O
(	(	(	(	(	N	O
75	CD	75	75	75	N	O
)	)	)	)	)	N	O
65	CD	65	65	65	N	O
(	(	(	(	(	N	O
43	CD	43	43	43	N	O
)	)	)	)	)	N	O
86	CD	86	86	86	N	O
(	(	(	(	(	N	O
61	CD	61	61	61	N	O
)	)	)	)	)	N	O
30	CD	30	30	30	N	O
(	(	(	(	(	N	O
21	CD	21	21	21	N	O
)	)	)	)	)	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
CLL	NNP	cll	cll	cll	Y	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
34%	CD	34%	34%	34%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
bilirubin	JJ	bilirubin	bilirubin	bilirubin	Y	B-AdverseReaction
elevations	NNS	elevations	elevation	elev	N	I-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
without	IN	without	without	without	N	B-Negation
associated	VBN	associated	associated	associ	N	O
significant	JJ	significant	significant	signific	N	B-Severity
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
and	CC	and	and	and	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
increased	JJ	increased	increased	increas	N	B-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Increases	NNS	increases	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
and	CC	and	and	and	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
4	CD	4	4	4	N	I-Severity
were	VBD	were	were	were	N	O
limited	VBN	limited	limited	limit	N	O
to	TO	to	to	to	N	O
1%	CD	1%	1%	1%	N	O
and	CC	and	and	and	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
may	MD	may	may	may	N	B-Factor
also	RB	also	also	also	N	O
have	VB	have	have	have	N	O
changes	NNS	changes	change	chang	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
their	PRP$	their	their	their	N	O
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
levels	NNS	levels	level	level	N	I-AdverseReaction
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
are	VBP	are	are	are	N	O
detected	VBN	detected	detected	detect	N	O
,	,	,	,	,	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
parameters	NNS	parameters	parameter	paramet	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
continued	VBN	continued	continued	continu	N	O
to	TO	to	to	to	N	O
ensure	VB	ensure	ensure	ensur	N	O
that	IN	that	that	that	N	O
further	JJ	further	further	further	N	O
deterioration	NN	deterioration	deterioration	deterior	N	O
does	VBZ	does	doe	doe	N	O
not	RB	not	not	not	N	O
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Non	NN	non	non	non	N	O

-	:	-	-	-	N	O
Hodgkin	NN	hodgkin	hodgkin	hodgkin	N	O
Lymphoma	NNP	lymphoma	lymphoma	lymphoma	Y	O

The	DT	the	the	the	N	O
data	NNS	data	data	data	N	O
described	VBD	described	described	describ	N	O
below	IN	below	below	below	N	O
reflect	NN	reflect	reflect	reflect	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
in	IN	in	in	in	N	O
176	CD	176	176	176	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
indolent	NN	indolent	indolent	indol	N	O
B	NNP	b	b	b	N	O
-	:	-	-	-	N	O
cell	NN	cell	cell	cell	N	O
NHL	NNP	nhl	nhl	nhl	N	O
treated	VBN	treated	treated	treat	N	O
in	IN	in	in	in	N	O
two	CD	two	two	two	N	O
single	JJ	single	single	singl	N	O
-	:	-	-	-	N	O
arm	NN	arm	arm	arm	N	O
studies	NNS	studies	study	studi	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
population	NN	population	population	popul	N	O
was	VBD	was	wa	wa	N	O
31	CD	31	31	31	N	O
-	:	-	-	-	N	O
84	CD	84	84	84	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
60%	CD	60%	60%	60%	N	O
male	NN	male	male	male	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
40%	CD	40%	40%	40%	N	O
female	NN	female	female	femal	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
race	NN	race	race	race	N	O
distribution	NN	distribution	distribution	distribut	N	O
was	VBD	was	wa	wa	N	O
89%	CD	89%	89%	89%	N	O
White	NNP	white	white	white	N	O
,	,	,	,	,	N	O
7%	CD	7%	7%	7%	N	O
Black	NNP	black	black	black	N	O
,	,	,	,	,	N	O
3%	CD	3%	3%	3%	N	O
Hispanic	NNP	hispanic	hispanic	hispan	N	O
,	,	,	,	,	N	O
1%	CD	1%	1%	1%	N	O
other	JJ	other	other	other	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
1%	CD	1%	1%	1%	N	O
Asian	JJ	asian	asian	asian	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
120	CD	120	120	120	N	O
mg	NNS	mg	mg	mg	N	O
m	RB	m	m	m	N	O
2	CD	2	2	2	N	O
intravenously	RB	intravenously	intravenously	intraven	N	O
on	IN	on	on	on	N	O
Days	NNS	days	day	day	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
2	CD	2	2	2	N	O
for	IN	for	for	for	N	O
up	RB	up	up	up	N	O
to	TO	to	to	to	N	O
eight	CD	eight	eight	eight	N	O
21	CD	21	21	21	N	O
-	:	-	-	-	N	O
day	NN	day	day	day	N	O
cycles	NNS	cycles	cycle	cycl	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
NHL	NNP	nhl	nhl	nhl	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
severity	NN	severity	severity	sever	N	O
,	,	,	,	,	N	O
are	VBP	are	are	are	N	O
shown	VBN	shown	shown	shown	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
hematologic	JJ	hematologic	hematologic	hematolog	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
nausea	JJ	nausea	nausea	nausea	Y	B-AdverseReaction
(	(	(	(	(	N	O
75%	CD	75%	75%	75%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
57%	CD	57%	57%	57%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
(	(	(	(	(	N	O
40%	CD	40%	40%	40%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
(	(	(	(	(	N	O
37%	CD	37%	37%	37%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
34%	CD	34%	34%	34%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
hematologic	NN	hematologic	hematologic	hematolog	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
fatigue	JJ	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
each	DT	each	each	each	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
3	CD	3	3	3	N	O
:	:	:	:	:	N	O
Non	NNP	non	non	non	N	O
-	:	-	-	-	N	O
Hematologic	NNP	hematologic	hematologic	hematolog	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
Occurring	NNP	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
Least	NNP	least	least	least	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
NHL	NNP	nhl	nhl	nhl	N	O
Patients	NNP	patients	patient	patient	N	O
Treated	NNP	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
by	IN	by	by	by	N	O
System	NNP	system	system	system	N	O
Organ	NNP	organ	organ	organ	N	O
Class	NNP	class	class	class	N	O
and	CC	and	and	and	N	O
Preferred	NNP	preferred	preferred	prefer	N	O
Term	NNP	term	term	term	N	O
(	(	(	(	(	N	O
N	NNP	n	n	n	N	O
176	CD	176	176	176	N	O
)	)	)	)	)	N	O

System	NNP	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
Number	NNP	number	number	number	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O

Preferred	JJ	preferred	preferred	prefer	N	O
term	NN	term	term	term	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O

Total	JJ	total	total	total	N	O
number	NN	number	number	number	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
1	CD	1	1	1	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
176	CD	176	176	176	N	O
(	(	(	(	(	N	O
100	CD	100	100	100	N	O
)	)	)	)	)	N	O
94	CD	94	94	94	N	O
(	(	(	(	(	N	O
53	CD	53	53	53	N	O
)	)	)	)	)	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
disorders	NNS	disorders	disorder	disord	N	O

Tachycardia	NNP	tachycardia	tachycardia	tachycardia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
132	CD	132	132	132	N	O
(	(	(	(	(	N	O
75	CD	75	75	75	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
71	CD	71	71	71	N	O
(	(	(	(	(	N	O
40	CD	40	40	40	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
65	CD	65	65	65	N	O
(	(	(	(	(	N	O
37	CD	37	37	37	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
51	CD	51	51	51	N	O
(	(	(	(	(	N	O
29	CD	29	29	29	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
15	CD	15	15	15	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Gastroesophageal	NNP	gastroesophageal	gastroesophageal	gastroesophag	N	B-AdverseReaction
reflux	VBZ	reflux	reflux	reflux	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
upper	JJ	upper	upper	upper	N	I-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
distension	NN	distension	distension	distens	N	I-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
101	CD	101	101	101	N	O
(	(	(	(	(	N	O
57	CD	57	57	57	N	O
)	)	)	)	)	N	O
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O

Pyrexia	$	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
59	CD	59	59	59	N	O
(	(	(	(	(	N	O
34	CD	34	34	34	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Chills	NNS	chills	chill	chill	Y	B-AdverseReaction
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Edema	NNP	edema	edema	edema	Y	B-AdverseReaction
peripheral	JJ	peripheral	peripheral	peripher	N	I-AdverseReaction
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
11	CD	11	11	11	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Chest	NNP	chest	chest	chest	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Infusion	NNP	infusion	infusion	infus	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Catheter	NNP	catheter	catheter	cathet	N	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
infestations	NNS	infestations	infestation	infest	N	O

Herpes	NNP	herpes	herpes	herp	N	B-AdverseReaction
zoster	NN	zoster	zoster	zoster	N	I-AdverseReaction
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
10	CD	10	10	10	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Pneumonia	NNP	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Febrile	NNP	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	CC	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

Oral	JJ	oral	oral	oral	N	B-AdverseReaction
candidiasis	NN	candidiasis	candidiasis	candidiasi	Y	I-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Nasopharyngitis	RB	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
31	CD	31	31	31	N	O
(	(	(	(	(	N	O
18	CD	18	18	18	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Anorexia	$	anorexia	anorexia	anorexia	Y	B-AdverseReaction
40	CD	40	40	40	N	O
(	(	(	(	(	N	O
23	CD	23	23	23	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
24	CD	24	24	24	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	RB	appetite	appetite	appetit	N	I-AdverseReaction
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Hypokalemia	$	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
9	CD	9	9	9	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O

Arthralgia	$	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Bone	NNP	bone	bone	bone	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Headache	$	headache	headache	headach	Y	B-AdverseReaction
36	CD	36	36	36	N	O
(	(	(	(	(	N	O
21	CD	21	21	21	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
13	CD	13	13	13	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Depression	NN	depression	depression	depress	Y	B-AdverseReaction
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	IN	cough	cough	cough	Y	B-AdverseReaction
38	CD	38	38	38	N	O
(	(	(	(	(	N	O
22	CD	22	22	22	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
28	CD	28	28	28	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O

Pharyngolaryngeal	NNP	pharyngolaryngeal	pharyngolaryngeal	pharyngolaryng	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Wheezing	VBG	wheezing	wheezing	wheez	Y	B-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Nasal	NNP	nasal	nasal	nasal	N	B-AdverseReaction
congestion	NN	congestion	congestion	congest	N	I-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Rash	NNP	rash	rash	rash	Y	B-AdverseReaction
28	CD	28	28	28	N	O
(	(	(	(	(	N	O
16	CD	16	16	16	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Night	NNP	night	night	night	N	B-AdverseReaction
sweats	VBZ	sweats	sweat	sweat	N	I-AdverseReaction
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Hyperhidrosis	NN	hyperhidrosis	hyperhidrosis	hyperhidrosi	Y	B-AdverseReaction
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
disorders	NNS	disorders	disorder	disord	N	O

Hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O

Patients	NNS	patients	patient	patient	N	O
may	MD	may	may	may	N	O
have	VB	have	have	have	N	O
reported	VBN	reported	reported	report	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
1	CD	1	1	1	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
.	.	.	.	.	N	O
NOTE	NN	note	note	note	N	O
:	:	:	:	:	N	O
Patients	NNS	patients	patient	patient	N	O
counted	VBN	counted	counted	count	N	O
only	RB	only	only	onli	N	O
once	RB	once	once	onc	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
preferred	JJ	preferred	preferred	prefer	N	O
term	NN	term	term	term	N	O
category	NN	category	category	categori	N	O
and	CC	and	and	and	N	O
once	RB	once	once	onc	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
system	NN	system	system	system	N	O
organ	JJ	organ	organ	organ	N	O
class	NN	class	class	class	N	O
category	NN	category	category	categori	N	O
.	.	.	.	.	N	O

Hematologic	NNP	hematologic	hematologic	hematolog	N	B-AdverseReaction
toxicities	NNS	toxicities	toxicity	toxic	N	I-AdverseReaction
,	,	,	,	,	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
values	NNS	values	value	valu	N	O
and	CC	and	and	and	N	O
CTC	NNP	ctc	ctc	ctc	N	O
grade	NN	grade	grade	grade	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
NHL	NNP	nhl	nhl	nhl	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
single	JJ	single	single	singl	N	O
arm	NN	arm	arm	arm	N	O
studies	NNS	studies	study	studi	N	O
combined	VBN	combined	combined	combin	N	O
are	VBP	are	are	are	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
4	CD	4	4	4	N	O
.	.	.	.	.	N	O

Clinically	RB	clinically	clinically	clinic	N	O
important	JJ	important	important	import	N	O
chemistry	NN	chemistry	chemistry	chemistri	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
values	NNS	values	value	valu	N	O
that	WDT	that	that	that	N	O
were	VBD	were	were	were	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsened	VBN	worsened	worsened	worsen	N	O
from	IN	from	from	from	N	O
baseline	NN	baseline	baseline	baselin	N	O
and	CC	and	and	and	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
at	IN	at	at	at	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
,	,	,	,	,	N	O
in	IN	in	in	in	N	O
NHL	NNP	nhl	nhl	nhl	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
in	IN	in	in	in	N	O
both	DT	both	both	both	N	O
single	JJ	single	single	singl	N	O
arm	NN	arm	arm	arm	N	O
studies	NNS	studies	study	studi	N	O
combined	VBN	combined	combined	combin	N	O
were	VBD	were	were	were	N	O
hyperglycemia	NNS	hyperglycemia	hyperglycemia	hyperglycemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
elevated	VBN	elevated	elevated	elev	N	B-AdverseReaction
creatinine	NN	creatinine	creatinine	creatinin	Y	I-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
hyponatremia	NN	hyponatremia	hyponatremia	hyponatremia	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hypocalcemia	NN	hypocalcemia	hypocalcemia	hypocalcemia	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

4	CD	4	4	4	N	O
:	:	:	:	:	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Hematology	NNP	hematology	hematology	hematolog	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	O
in	IN	in	in	in	N	O
Patients	NNPS	patients	patient	patient	N	O
Who	WP	who	who	who	N	O
Received	VBD	received	received	receiv	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
NHL	NNP	nhl	nhl	nhl	N	O
Studies	NNPS	studies	study	studi	N	O

Percent	NN	percent	percent	percent	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O

Hematology	NNP	hematology	hematology	hematolog	N	O
variable	JJ	variable	variable	variabl	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grades	NNP	grades	grade	grade	N	O
3	CD	3	3	3	N	O
4	CD	4	4	4	N	O

Lymphocytes	NNS	lymphocytes	lymphocyte	lymphocyt	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
99	CD	99	99	99	N	O
94	CD	94	94	94	N	O

Leukocytes	NNS	leukocytes	leukocyte	leukocyt	N	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
94	CD	94	94	94	N	O
56	CD	56	56	56	N	O

Hemoglobin	NNP	hemoglobin	hemoglobin	hemoglobin	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
88	CD	88	88	88	N	O
11	CD	11	11	11	N	O

Neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
86	CD	86	86	86	N	O
60	CD	60	60	60	N	O

Platelets	NNS	platelets	platelet	platelet	N	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
86	CD	86	86	86	N	O
25	CD	25	25	25	N	O

In	IN	in	in	in	N	O
both	DT	both	both	both	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
regardless	RB	regardless	regardless	regardless	N	O
of	IN	of	of	of	N	O
causality	NN	causality	causality	causal	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
37%	CD	37%	37%	37%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
and	CC	and	and	and	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
important	JJ	important	important	import	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
experience	NN	experience	experience	experi	N	O
were	VBD	were	were	were	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
cardiac	JJ	cardiac	cardiac	cardiac	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
,	,	,	,	,	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
,	,	,	,	,	N	O
pulmonary	JJ	pulmonary	pulmonary	pulmonari	N	B-AdverseReaction
fibrosis	NN	fibrosis	fibrosis	fibrosi	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
myelodysplastic	JJ	myelodysplastic	myelodysplastic	myelodysplast	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
.	.	.	.	.	N	O

Serious	JJ	serious	serious	seriou	N	O

drug	NN	drug	drug	drug	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
included	VBD	included	included	includ	N	O
myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	B-AdverseReaction
,	,	,	,	,	N	O
infection	NN	infection	infection	infect	Y	B-AdverseReaction
,	,	,	,	,	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
tumor	NN	tumor	tumor	tumor	N	B-AdverseReaction
lysis	NN	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
and	CC	and	and	and	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
[	VBP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5	CD	5	5	5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
less	RBR	less	le	less	N	O
frequently	RB	frequently	frequently	frequent	N	O
but	CC	but	but	but	N	O
possibly	RB	possibly	possibly	possibl	N	B-Factor
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
treatment	NN	treatment	treatment	treatment	N	O
were	VBD	were	were	were	N	O
hemolysis	NN	hemolysis	hemolysis	hemolysi	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysgeusia	JJ	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
taste	NN	taste	taste	tast	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
atypical	JJ	atypical	atypical	atyp	N	B-AdverseReaction
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	I-AdverseReaction
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
herpes	NNS	herpes	herpes	herp	N	B-AdverseReaction
zoster	NN	zoster	zoster	zoster	N	I-AdverseReaction
,	,	,	,	,	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
dermatitis	NN	dermatitis	dermatitis	dermat	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
necrosis	NN	necrosis	necrosis	necrosi	Y	I-AdverseReaction
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
:	:	:	:	:	N	O
anaphylaxis	NN	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
;	:	;	;	;	N	O
and	CC	and	and	and	N	O
injection	NN	injection	injection	inject	Y	B-AdverseReaction
or	CC	or	or	or	N	O
infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
site	NN	site	site	site	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
phlebitis	NN	phlebitis	phlebitis	phlebiti	Y	I-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	I-AdverseReaction
,	,	,	,	,	N	O
irritation	NN	irritation	irritation	irrit	N	I-AdverseReaction
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
swelling	VBG	swelling	swelling	swell	Y	I-AdverseReaction
;	:	;	;	;	N	O
pneumocystis	NN	pneumocystis	pneumocystis	pneumocysti	N	B-AdverseReaction
jiroveci	NN	jiroveci	jiroveci	jiroveci	N	I-AdverseReaction
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	I-AdverseReaction
and	CC	and	and	and	N	O
pneumonitis	NN	pneumonitis	pneumonitis	pneumon	Y	B-AdverseReaction
.	.	.	.	.	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
including	VBG	including	including	includ	N	O
SJS	NNP	sjs	sjs	sj	N	B-AdverseReaction
and	CC	and	and	and	N	O
TEN	NNP	ten	ten	ten	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
when	WRB	when	when	when	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
with	IN	with	with	with	N	O
allopurinol	NNS	allopurinol	allopurinol	allopurinol	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
medications	NNS	medications	medication	medic	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
these	DT	these	these	these	N	O
syndromes	NNS	syndromes	syndrome	syndrom	N	O
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	RB	)]	)]	)]	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	B-AdverseReaction
:	:	:	:	:	N	O
Delay	NN	delay	delay	delay	N	O
or	CC	or	or	or	N	O
reduce	VB	reduce	reduce	reduc	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Restart	NNP	restart	restart	restart	N	O
treatment	NN	treatment	treatment	treatment	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
ANC	NNP	anc	anc	anc	N	O
and	CC	and	and	and	N	O
platelet	NN	platelet	platelet	platelet	N	O
count	NN	count	count	count	N	O
recovery	NN	recovery	recovery	recoveri	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
Complications	NNS	complications	complication	complic	N	O
of	IN	of	of	of	N	O
myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
fever	NN	fever	fever	fever	Y	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
promptly	RB	promptly	promptly	promptli	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
Infusion	NNP	infusion	infusion	infus	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Severe	NNP	severe	severe	sever	N	O
and	CC	and	and	and	N	O
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
;	:	;	;	;	N	O
monitor	NN	monitor	monitor	monitor	N	O
clinically	RB	clinically	clinically	clinic	N	O
and	CC	and	and	and	N	O
discontinue	VB	discontinue	discontinue	discontinu	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
.	.	.	.	.	N	O

Pre	NNP	pre	pre	pre	N	O
-	:	-	-	-	N	O
medicate	NN	medicate	medicate	medic	N	O
in	IN	in	in	in	N	O
subsequent	JJ	subsequent	subsequent	subsequ	N	O
cycles	NNS	cycles	cycle	cycl	N	O
for	IN	for	for	for	N	O
milder	NN	milder	milder	milder	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
Lysis	NNP	lysis	lysis	lysi	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
:	:	:	:	:	N	O
Acute	NNP	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	B-AdverseReaction
;	:	;	;	;	N	O
anticipate	NN	anticipate	anticipate	anticip	N	O
and	CC	and	and	and	N	O
use	VB	use	use	use	N	O
supportive	JJ	supportive	supportive	support	N	O
measures	NNS	measures	measure	measur	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Skin	JJ	skin	skin	skin	N	B-AdverseReaction
Reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
:	:	:	:	:	N	O
Discontinue	NNP	discontinue	discontinue	discontinu	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
skin	JJ	skin	skin	skin	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
SJS	NNP	sjs	sjs	sj	N	B-AdverseReaction
and	CC	and	and	and	N	O
TEN	NNP	ten	ten	ten	Y	B-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
when	WRB	when	when	when	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
with	IN	with	with	with	N	O
allopurinol	NNS	allopurinol	allopurinol	allopurinol	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
medications	NNS	medications	medication	medic	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
these	DT	these	these	these	N	O
syndromes	NNS	syndromes	syndrome	syndrom	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O

Other	JJ	other	other	other	N	O
Malignancies	NNS	malignancies	malignancy	malign	N	B-AdverseReaction
:	:	:	:	:	N	O
Pre	NNP	pre	pre	pre	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
malignant	NN	malignant	malignant	malign	N	I-AdverseReaction
and	CC	and	and	and	N	O
malignant	JJ	malignant	malignant	malign	N	B-AdverseReaction
diseases	NNS	diseases	disease	diseas	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O

Extravasation	NN	extravasation	extravasation	extravas	Y	B-AdverseReaction
:	:	:	:	:	N	O
Assure	NN	assure	assure	assur	N	O
good	JJ	good	good	good	N	O
venous	JJ	venous	venous	venou	N	O
access	NN	access	access	access	N	O
and	CC	and	and	and	N	O
monitor	NN	monitor	monitor	monitor	N	O
infusion	NN	infusion	infusion	infus	Y	O
site	NN	site	site	site	N	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O

Embryo	NNP	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

Women	NNS	women	woman	women	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
becoming	VBG	becoming	becoming	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
when	WRB	when	when	when	N	O
receiving	VBG	receiving	receiving	receiv	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.8	CD	5.8	5.8	5.8	N	O
,	,	,	,	,	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	O

TREANDA	NN	treanda	treanda	treanda	N	O

caused	VBN	caused	caused	caus	N	O
severe	JJ	severe	severe	sever	N	B-Severity
myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	B-AdverseReaction
(	(	(	(	(	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
98%	CD	98%	98%	98%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
NHL	NNP	nhl	nhl	nhl	N	O
studies	NNS	studies	study	studi	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
Table	NNP	table	table	tabl	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Three	CD	three	three	three	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
died	VBD	died	died	die	N	B-AdverseReaction
from	IN	from	from	from	N	O
myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
;	:	;	;	;	N	O
one	CD	one	one	one	N	O
each	DT	each	each	each	N	O
from	IN	from	from	from	N	O
neutropenic	JJ	neutropenic	neutropenic	neutropen	N	B-AdverseReaction
sepsis	NN	sepsis	sepsis	sepsi	Y	I-AdverseReaction
,	,	,	,	,	N	O
diffuse	IN	diffuse	diffuse	diffus	N	B-AdverseReaction
alveolar	JJ	alveolar	alveolar	alveolar	N	I-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
from	IN	from	from	from	N	O
an	DT	an	an	an	N	O
opportunistic	JJ	opportunistic	opportunistic	opportunist	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
CMV	NNP	cmv	cmv	cmv	N	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
event	NN	event	event	event	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	O
,	,	,	,	,	N	O
monitor	NN	monitor	monitor	monitor	N	O
leukocytes	NNS	leukocytes	leukocyte	leukocyt	N	O
,	,	,	,	,	N	O
platelets	NNS	platelets	platelet	platelet	N	O
,	,	,	,	,	N	O
hemoglobin	NN	hemoglobin	hemoglobin	hemoglobin	Y	O
(	(	(	(	(	N	O
Hgb	NNP	hgb	hgb	hgb	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
neutrophils	NNS	neutrophils	neutrophil	neutrophil	Y	O
frequently	RB	frequently	frequently	frequent	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
were	VBD	were	were	were	N	O
monitored	VBN	monitored	monitored	monitor	N	O
every	DT	every	every	everi	N	O
week	NN	week	week	week	N	O
initially	RB	initially	initially	initi	N	O
.	.	.	.	.	N	O

Hematologic	NNP	hematologic	hematologic	hematolog	N	O
nadirs	NNS	nadirs	nadir	nadir	N	O
were	VBD	were	were	were	N	O
observed	VBN	observed	observed	observ	N	O
predominantly	RB	predominantly	predominantly	predominantli	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
third	JJ	third	third	third	N	O
week	NN	week	week	week	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	O
may	MD	may	may	may	N	O
require	VB	require	require	requir	N	O
dose	JJ	dose	dose	dose	N	O
delays	NNS	delays	delay	delay	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
subsequent	JJ	subsequent	subsequent	subsequ	N	O
dose	NN	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
if	IN	if	if	if	N	O
recovery	NN	recovery	recovery	recoveri	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
recommended	VBN	recommended	recommended	recommend	N	O
values	NNS	values	value	valu	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
occurred	VBN	occurred	occurred	occur	N	O
by	IN	by	by	by	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
day	NN	day	day	day	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
next	JJ	next	next	next	N	O
scheduled	JJ	scheduled	scheduled	schedul	N	O
cycle	NN	cycle	cycle	cycl	N	O
.	.	.	.	.	N	O

Prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
next	JJ	next	next	next	N	O
cycle	NN	cycle	cycle	cycl	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
ANC	NNP	anc	anc	anc	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
1	CD	1	1	1	N	O
x	JJ	x	x	x	N	O
10	CD	10	10	10	N	O
9	CD	9	9	9	N	O
L	NNP	l	l	l	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
platelet	NN	platelet	platelet	platelet	N	O
count	NN	count	count	count	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
75	CD	75	75	75	N	O
x	JJ	x	x	x	N	O
10	CD	10	10	10	N	O
9	CD	9	9	9	N	O
L.	NNP	l.	l.	l.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)]	NN	)]	)]	)]	N	O

5.2	CD	5.2	5.2	5.2	N	O
Infections	NNS	infections	infection	infect	N	O

Infection	NN	infection	infection	infect	Y	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
septic	JJ	septic	septic	septic	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	B-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
adult	NN	adult	adult	adult	N	O
and	CC	and	and	and	N	O
pediatric	JJ	pediatric	pediatric	pediatr	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	B-AdverseReaction
following	VBG	following	following	follow	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
are	VBP	are	are	are	N	O
more	RBR	more	more	more	N	O
susceptible	JJ	susceptible	susceptible	suscept	N	B-Factor
to	TO	to	to	to	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
.	.	.	.	.	N	O

Advise	NN	advise	advise	advis	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
myelosuppression	NN	myelosuppression	myelosuppression	myelosuppress	Y	O
following	VBG	following	following	follow	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
treatment	NN	treatment	treatment	treatment	N	O
to	TO	to	to	to	N	O
contact	VB	contact	contact	contact	N	O
a	DT	a	a	a	N	O
physician	NN	physician	physician	physician	N	O
if	IN	if	if	if	N	O
they	PRP	they	they	they	N	O
have	VBP	have	have	have	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
or	CC	or	or	or	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
infection	NN	infection	infection	infect	Y	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Anaphylaxis	NNP	anaphylaxis	anaphylaxis	anaphylaxi	Y	O
and	CC	and	and	and	N	O
Infusion	NNP	infusion	infusion	infus	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Infusion	NN	infusion	infusion	infus	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
to	TO	to	to	to	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
have	VB	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
commonly	RB	commonly	commonly	commonli	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

Symptoms	NNP	symptoms	symptom	symptom	N	O
include	VBP	include	include	includ	N	O
fever	NN	fever	fever	fever	Y	B-AdverseReaction
,	,	,	,	,	N	O
chills	NNS	chills	chill	chill	Y	B-AdverseReaction
,	,	,	,	,	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
and	CC	and	and	and	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
rare	JJ	rare	rare	rare	N	O
instances	NNS	instances	instance	instanc	N	O
severe	JJ	severe	severe	sever	N	B-Severity
anaphylactic	JJ	anaphylactic	anaphylactic	anaphylact	N	B-AdverseReaction
and	CC	and	and	and	N	O
anaphylactoid	JJ	anaphylactoid	anaphylactoid	anaphylactoid	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
second	JJ	second	second	second	N	O
and	CC	and	and	and	N	O
subsequent	JJ	subsequent	subsequent	subsequ	N	O
cycles	NNS	cycles	cycle	cycl	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
clinically	RB	clinically	clinically	clinic	N	O
and	CC	and	and	and	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
drug	NN	drug	drug	drug	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Ask	NNP	ask	ask	ask	N	O
patients	NNS	patients	patient	patient	N	O
about	IN	about	about	about	N	O
symptoms	NNS	symptoms	symptom	symptom	N	O
suggestive	JJ	suggestive	suggestive	suggest	N	O
of	IN	of	of	of	N	O
infusion	NN	infusion	infusion	infus	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
after	IN	after	after	after	N	O
their	PRP$	their	their	their	N	O
first	JJ	first	first	first	N	O
cycle	NN	cycle	cycle	cycl	N	O
of	IN	of	of	of	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experience	VBP	experience	experience	experi	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
worse	JJR	worse	worse	wors	N	O
allergic	JJ	allergic	allergic	allerg	N	O
-	:	-	-	-	N	O
type	NN	type	type	type	N	O
reactions	NNS	reactions	reaction	reaction	N	O
should	MD	should	should	should	N	O
not	RB	not	not	not	N	O
be	VB	be	be	be	N	O
rechallenged	VBN	rechallenged	rechallenged	rechalleng	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
measures	NNS	measures	measure	measur	N	O
to	TO	to	to	to	N	O
prevent	VB	prevent	prevent	prevent	N	O
severe	JJ	severe	severe	sever	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
antihistamines	NNS	antihistamines	antihistamine	antihistamin	N	O
,	,	,	,	,	N	O
antipyretics	NNS	antipyretics	antipyretic	antipyret	N	O
and	CC	and	and	and	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
in	IN	in	in	in	N	O
subsequent	JJ	subsequent	subsequent	subsequ	N	O
cycles	NNS	cycles	cycle	cycl	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
experienced	VBN	experienced	experienced	experienc	N	O
Grade	NNP	grade	grade	grade	N	O
1	CD	1	1	1	N	O
or	CC	or	or	or	N	O
2	CD	2	2	2	N	O
infusion	NN	infusion	infusion	infus	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	O
4	CD	4	4	4	N	O
infusion	NN	infusion	infusion	infus	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
.	.	.	.	.	N	O

Consider	VB	consider	consider	consid	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
for	IN	for	for	for	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
infusions	NNS	infusions	infusion	infus	N	O
reactions	NNS	reactions	reaction	reaction	N	O
as	IN	as	a	as	N	O
clinically	RB	clinically	clinically	clinic	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
considering	VBG	considering	considering	consid	N	O
individual	JJ	individual	individual	individu	N	O
benefits	NNS	benefits	benefit	benefit	N	O
,	,	,	,	,	N	O
risks	NNS	risks	risk	risk	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
supportive	JJ	supportive	supportive	support	N	O
care	NN	care	care	care	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Tumor	NNP	tumor	tumor	tumor	N	O
Lysis	NNP	lysis	lysis	lysi	N	O
Syndrome	NNP	syndrome	syndrome	syndrom	N	O

Tumor	NNP	tumor	tumor	tumor	N	B-AdverseReaction
lysis	VBD	lysis	lysis	lysi	N	I-AdverseReaction
syndrome	RB	syndrome	syndrome	syndrom	N	I-AdverseReaction
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
treatment	NN	treatment	treatment	treatment	N	O
has	VBZ	has	ha	ha	N	O
occurred	VBN	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
reports	NNS	reports	report	report	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
onset	NN	onset	onset	onset	N	O
tends	VBZ	tends	tends	tend	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
treatment	NN	treatment	treatment	treatment	N	O
cycle	NN	cycle	cycle	cycl	N	O
of	IN	of	of	of	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
and	CC	and	and	and	N	O
,	,	,	,	,	N	O
without	IN	without	without	without	N	O
intervention	NN	intervention	intervention	intervent	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	B-Factor
lead	VB	lead	lead	lead	Y	O
to	TO	to	to	to	N	O
acute	VB	acute	acute	acut	N	B-AdverseReaction
renal	JJ	renal	renal	renal	N	I-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
and	CC	and	and	and	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Preventive	JJ	preventive	preventive	prevent	N	O
measures	NNS	measures	measure	measur	N	O
include	VBP	include	include	includ	N	O
vigorous	JJ	vigorous	vigorous	vigor	N	O
hydration	NN	hydration	hydration	hydrat	N	O
and	CC	and	and	and	N	O
close	JJ	close	close	close	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
blood	NN	blood	blood	blood	N	O
chemistry	NN	chemistry	chemistry	chemistri	N	O
,	,	,	,	,	N	O
particularly	RB	particularly	particularly	particularli	N	O
potassium	NN	potassium	potassium	potassium	Y	O
and	CC	and	and	and	N	O
uric	JJ	uric	uric	uric	N	O
acid	NN	acid	acid	acid	N	O
levels	NNS	levels	level	level	N	O
.	.	.	.	.	N	O

Allopurinol	NNP	allopurinol	allopurinol	allopurinol	N	O
has	VBZ	has	ha	ha	N	O
also	RB	also	also	also	N	O
been	VBN	been	been	been	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
beginning	NN	beginning	beginning	begin	N	O
of	IN	of	of	of	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

However	RB	however	however	howev	N	O
,	,	,	,	,	N	O
there	EX	there	there	there	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
an	DT	an	an	an	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	B-Factor
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	B-Severity
skin	NN	skin	skin	skin	N	B-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
when	WRB	when	when	when	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
and	CC	and	and	and	N	O
allopurinol	NNS	allopurinol	allopurinol	allopurinol	N	O
are	VBP	are	are	are	N	O
administered	VBN	administered	administered	administ	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNS	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Skin	NNP	skin	skin	skin	N	O
Reactions	NNS	reactions	reaction	reaction	N	O

Skin	NNP	skin	skin	skin	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
with	IN	with	with	with	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
treatment	NN	treatment	treatment	treatment	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
safety	NN	safety	safety	safeti	N	O
reports	NNS	reports	report	report	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction
,	,	,	,	,	N	O
toxic	JJ	toxic	toxic	toxic	N	B-AdverseReaction
skin	NN	skin	skin	skin	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
and	CC	and	and	and	N	O
bullous	JJ	bullous	bullous	bullou	N	B-AdverseReaction
exanthema	NN	exanthema	exanthema	exanthema	Y	I-AdverseReaction
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
events	NNS	events	event	event	N	O
occurred	VBD	occurred	occurred	occur	N	O
when	WRB	when	when	when	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
was	VBD	was	wa	wa	N	O
given	VBN	given	given	given	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
other	JJ	other	other	other	N	O
anticancer	NN	anticancer	anticancer	anticanc	N	O
agents	NNS	agents	agent	agent	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
a	DT	a	a	a	N	O
study	NN	study	study	studi	N	O
of	IN	of	of	of	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
(	(	(	(	(	N	O
90	CD	90	90	90	N	O
mg	NN	mg	mg	mg	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
rituximab	NN	rituximab	rituximab	rituximab	N	O
,	,	,	,	,	N	O
one	CD	one	one	one	N	O
case	NN	case	case	case	N	O
of	IN	of	of	of	N	O
toxic	NN	toxic	toxic	toxic	N	B-AdverseReaction
epidermal	JJ	epidermal	epidermal	epiderm	N	I-AdverseReaction
necrolysis	NN	necrolysis	necrolysis	necrolysi	N	I-AdverseReaction
(	(	(	(	(	N	O
TEN	NNP	ten	ten	ten	Y	B-AdverseReaction
)	)	)	)	)	N	O
occurred	VBD	occurred	occurred	occur	N	O
.	.	.	.	.	N	O

TEN	NN	ten	ten	ten	Y	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
rituximab	NN	rituximab	rituximab	rituximab	N	O
(	(	(	(	(	N	O
see	VB	see	see	see	N	O
rituximab	JJ	rituximab	rituximab	rituximab	N	O
package	NN	package	package	packag	N	O
insert	NN	insert	insert	insert	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Cases	NNS	cases	case	case	N	O
of	IN	of	of	of	N	O
Stevens	NNP	stevens	stevens	steven	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Johnson	NNP	johnson	johnson	johnson	N	I-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
(	(	(	(	(	N	O
SJS	NNP	sjs	sjs	sj	N	B-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
TEN	NNP	ten	ten	ten	Y	B-AdverseReaction
,	,	,	,	,	N	O
some	DT	some	some	some	N	O
fatal	NN	fatal	fatal	fatal	N	B-AdverseReaction
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
when	WRB	when	when	when	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
was	VBD	was	wa	wa	N	O
administered	VBN	administered	administered	administ	N	O
concomitantly	RB	concomitantly	concomitantly	concomitantli	N	O
with	IN	with	with	with	N	O
allopurinol	NNS	allopurinol	allopurinol	allopurinol	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
medications	NNS	medications	medication	medic	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
these	DT	these	these	these	N	O
syndromes	NNS	syndromes	syndrome	syndrom	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
determined	VBN	determined	determined	determin	N	O
.	.	.	.	.	N	O

Where	WRB	where	where	where	N	O
skin	JJ	skin	skin	skin	N	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
occur	VBP	occur	occur	occur	N	O
,	,	,	,	,	N	O
they	PRP	they	they	they	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
progressive	JJ	progressive	progressive	progress	N	O
and	CC	and	and	and	N	O
increase	VB	increase	increase	increas	N	O
in	IN	in	in	in	N	O
severity	NN	severity	severity	sever	N	O
with	IN	with	with	with	N	O
further	JJ	further	further	further	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
skin	JJ	skin	skin	skin	N	O
reactions	NNS	reactions	reaction	reaction	N	O
closely	RB	closely	closely	close	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
skin	JJ	skin	skin	skin	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
severe	JJ	severe	severe	sever	N	O
or	CC	or	or	or	N	O
progressive	JJ	progressive	progressive	progress	N	O
,	,	,	,	,	N	O
withhold	VBD	withhold	withhold	withhold	N	O
or	CC	or	or	or	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Other	JJ	other	other	other	N	O
Malignancies	NNS	malignancies	malignancy	malign	N	O

There	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
reports	NNS	reports	report	report	N	O
of	IN	of	of	of	N	O
pre	JJ	pre	pre	pre	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
malignant	NN	malignant	malignant	malign	N	I-AdverseReaction
and	CC	and	and	and	N	O
malignant	JJ	malignant	malignant	malign	N	B-AdverseReaction
diseases	NNS	diseases	disease	diseas	N	I-AdverseReaction
that	WDT	that	that	that	N	O
have	VBP	have	have	have	N	O
developed	VBN	developed	developed	develop	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
myelodysplastic	JJ	myelodysplastic	myelodysplastic	myelodysplast	N	B-AdverseReaction
syndrome	NN	syndrome	syndrome	syndrom	N	I-AdverseReaction
,	,	,	,	,	N	O
myeloproliferative	JJ	myeloproliferative	myeloproliferative	myeloprolif	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
acute	JJ	acute	acute	acut	N	B-AdverseReaction
myeloid	NN	myeloid	myeloid	myeloid	N	I-AdverseReaction
leukemia	NN	leukemia	leukemia	leukemia	Y	I-AdverseReaction
and	CC	and	and	and	N	O
bronchial	JJ	bronchial	bronchial	bronchial	N	B-AdverseReaction
carcinoma	NN	carcinoma	carcinoma	carcinoma	Y	I-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
therapy	NN	therapy	therapy	therapi	N	O
has	VBZ	has	ha	ha	N	O
not	RB	not	not	not	N	O
been	VBN	been	been	been	N	O
determined	VBN	determined	determined	determin	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Extravasation	NNP	extravasation	extravasation	extravas	Y	O
Injury	NNP	injury	injury	injuri	Y	O

TREANDA	NNP	treanda	treanda	treanda	N	O
extravasations	NNS	extravasations	extravasation	extravas	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
post	NN	post	post	post	N	O
marketing	NN	marketing	marketing	market	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
hospitalizations	NNS	hospitalizations	hospitalization	hospit	N	O
from	IN	from	from	from	N	O
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
marked	VBD	marked	marked	mark	N	B-Severity
swelling	NN	swelling	swelling	swell	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
pain	NN	pain	pain	pain	Y	B-AdverseReaction
.	.	.	.	.	N	O

Assure	RB	assure	assure	assur	N	O
good	JJ	good	good	good	N	O
venous	JJ	venous	venous	venou	N	O
access	NN	access	access	access	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
starting	VBG	starting	starting	start	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
infusion	NN	infusion	infusion	infus	Y	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
the	DT	the	the	the	N	O
intravenous	JJ	intravenous	intravenous	intraven	N	O
infusion	NN	infusion	infusion	infus	Y	O
site	NN	site	site	site	N	O
for	IN	for	for	for	N	O
redness	NN	redness	redness	red	Y	O
,	,	,	,	,	N	O
swelling	VBG	swelling	swelling	swell	Y	O
,	,	,	,	,	N	O
pain	NN	pain	pain	pain	Y	O
,	,	,	,	,	N	O
infection	NN	infection	infection	infect	Y	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
necrosis	NN	necrosis	necrosis	necrosi	Y	O
during	IN	during	during	dure	N	O
and	CC	and	and	and	N	O
after	IN	after	after	after	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
TREANDA	NNP	treanda	treanda	treanda	N	O
.	.	.	.	.	N	O

5.8	CD	5.8	5.8	5.8	N	O
Embryo	NNP	embryo	embryo	embryo	N	O
-	:	-	-	-	N	O
fetal	JJ	fetal	fetal	fetal	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

TREANDA	NNP	treanda	treanda	treanda	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

Single	NNP	single	single	singl	N	O
intraperitoneal	NN	intraperitoneal	intraperitoneal	intraperiton	N	O
doses	NNS	doses	dos	dose	N	O
of	IN	of	of	of	N	O
bendamustine	NN	bendamustine	bendamustine	bendamustin	N	O
in	IN	in	in	in	N	O
mice	NN	mice	mouse	mice	N	B-Animal
and	CC	and	and	and	N	O
rats	NNS	rats	rat	rat	N	B-Animal
administered	VBD	administered	administered	administ	N	O
during	IN	during	during	dure	N	O
organogenesis	NN	organogenesis	organogenesis	organogenesi	N	O
caused	VBD	caused	caused	caus	N	O
an	DT	an	an	an	N	O
increase	NN	increase	increase	increas	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
resorptions	NNS	resorptions	resorption	resorpt	N	I-AdverseReaction
,	,	,	,	,	N	O
skeletal	JJ	skeletal	skeletal	skelet	N	B-AdverseReaction
and	CC	and	and	and	N	O
visceral	JJ	visceral	visceral	viscer	N	B-AdverseReaction
malformations	NNS	malformations	malformation	malform	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
decreased	VBD	decreased	decreased	decreas	N	B-AdverseReaction
fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
body	NN	body	body	bodi	N	I-AdverseReaction
weights	NNS	weights	weight	weight	N	I-AdverseReaction
.	.	.	.	.	N	O

[	NNS	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)]	NN	)]	)]	)]	N	O

